Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Reuters NewMedia - Tuesday December 22, 1998
DuPont Pharmaceuticals, the drug unit of the industrial giant DuPont, also said the Texas HIV Medications Advisory Committee had recommended Sustiva be added to that state's list of approved drugs. Once a drug is on such a list, most insurers will cover its use by patients.
When approved in Texas, Sustiva will have been approved by 46 states, plus the District of Columbia, for such drug lists. DuPont said Sustiva is also on the Medicaid lists of 49 states and the District of Columbia.
The U.S. Food and Drug Administration approved Sustiva in September as part of the agency's fast-track program that speeds up the review process of drugs designed to treat life-threatening diseases.
DuPont said more than 30,000 patients in the United States have begun taking Sustiva since DuPont Pharmaceuticals launched the drug in September. Out of that 30,000, some 8,000 patients receive the drug through the company's expanded access programs, which provide the drug to people for free if their doctors think they would benefit from it.
981222
RE981207
Copyright © 1998 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .